The Warsaw Stock Exchange-listed Polish medtech company has signed an agreement with global cardiac diagnostics leader, Australian-based CardioScan, which operates across North America, Asia, Oceania, and Europe. Under the agreement, Medicalgorithmics’ innovative software – the DeepRhythm Platform (DRP) and DeepRhythmAI (DRAI) artificial intelligence algorithms – will be available to CardioScan’s clients after integration and regulatory approval. This is the second partnership in Australia and the twelfth agreement signed by the Polish medtech firm this year.
CardioScan is a seasoned company with over 40 years of experience, utilizing leading technologies, software, and clinical expertise to deliver comprehensive, high-quality diagnostic services. Founded by A/Prof Harry Mond, one of the world’s foremost experts in EKG and Holter test interpretation, CardioScan has successfully conducted over 20 million cardiac tests. This partnership, focused on leveraging DRAI and DRP, confirms the world-class innovation and quality of Medicalgorithmics’ software.
“Signing the agreement with CardioScan is a significant step for us, due to the company’s global reputation, dynamic growth, and scale of operations. CardioScan is one of the world’s largest cardiac diagnostic service providers, operating under the international IDTF model. We believe that the results of the DRAI Martini study published earlier this year in Nature Medicine, which confirmed the high effectiveness and quality of our AI algorithms, will drive further interest in our technology. We expect our share in the global EKG diagnostics market to continue growing steadily” said Dr. Kris Siemionow, MD, PhD, Management Board Member and Group CEO at Medicalgorithmics.
“Following our successful corporate transformation – which involved separating software from Holter hardware and opening up to third-party integrations – we are consistently executing our dynamic expansion strategy. We’re signing more contracts, especially for the use of our innovative algorithms and software. This shows just how far we’ve come – today, we’re in a completely different position than we were just a few years ago” added Jarosław Jerzakowski, COO Medicalgorithmics.
2025 marks a significant increase in interest in Medicalgorithmics’ products and an acceleration in acquiring new clients. Since the beginning of the year, the company has signed 12 new agreements with partners in the U.S., Canada, Australia, Korea, Turkey, and other European countries. For comparison, the company signed a total of 13 new clients in all of 2024. At the same time, the number of EKG tests performed by the Polish medtech firm is rising sharply – reaching 92,000 tests in Q1 2025, nearly 100% year-on-year growth.